Table 2. Review of Corticosteroid Therapy in Patients With COVID-19.
| Published RCTs/cohort studies of corticosteroid therapy in COVID-19 | Absolute difference in mortality rate (Rx group vs. control group) | Estimated number needed to treat to save one life |
|---|---|---|
| Methylprednisolone - hospital patients [54] | 5.9% vs. 42.9% | 2.7 |
| Methylprednisolone - ICU patients [44] | 7.2% vs. 23.3% | 6.2 |
| Methylprednisolone - hospital patients [35] | 13.6% vs. 26.3% | 7.8 |
| Methylprednisolone - ARDS patients [53] | 46.0% vs. 61.8% | 6.3 |
| Methylprednisolone - percent on oxygen [36] | 13.9% vs. 23.9% | 10.0 |
| CoDEX - dexamethasone - mechanical ventilation [52] | 56.3% vs. 61.5% | 19.2 |
| RECOVERY trial (dexamethasone) [51] | ||
| Percent on oxygen | 23.3% vs. 26.2% | 28.6 |
| Percent on mechanical ventilation | 29.3% vs. 41.4% | 8.4 |
| Hydrocortisone - CAPE COVID - ICU patients [60] | 14.7% vs. 27.4% | 7.9 |
| Hydrocortisone - REMAP-CAP - ICU patients [49] | 28% vs. 33% | 20.0 |
Table is provided by Pierre Kory Flccc.org. COVID-19: coronavirus disease 2019.